Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers of next-generation precision medicines
BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Precede Biosciences, a precision diagnostics and data company focused on enabling the next generation of precision medicines, today announced that it has secured $83.5 million in total financing, including $63.5 million in Series B equity and a $20 million strategic, non-dilutive credit facility.
The Precede Bio platform supports the development and clinical use of today's most intensively studied cancer therapies. For these medicines, target expression and pathway activity, rather than single genomic alterations, are the defining biomarkers. These therapies include drug-, radio-, and immune-conjugates, as well as other advanced mono- and multi-specific targeted modalities. The financing will support scaling of the company's platform to meet rapidly growing demand from developers of these next-generation precision medicines.
The Series B includes continued support from Precede Bio's existing investor syndicate and the addition of new strategic and institutional investors, reflecting broad conviction in the company's mission, progress, and commercial trajectory. The expanded investor base adds partners with deep capabilities in diagnostics commercialization and health system adoption, ...
